A Phase I Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD4144
← catalyst calendarNCT07783308 · readout in 276 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
30estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-24
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-08-24 | estimated | When the study began enrolling |
| Primary completion | 2027-05-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hepatic Impairment
Intervention
- Drug: AZD4144
Primary outcomes
what the primary-completion date above is the date OFPK parameters AUCinf
measured Day 0 through Day 7 or 9
PK parameter AUClast
measured Day 0 through Day 7 or 9
PK parameters AUC(0-144)
measured Day 0 through Day 7
PK parameter Cmax
measured Day 0 through Day 7 or 9
Related
AZN · their whole pipeline · Congress trades in AZN
AZN's other studiesmost recently updated first
- AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies Phase 1 · Active, not recruiting
- A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01) Phase 3 · Active, not recruiting
- PASS of Paediatric Patients Initiating Selumetinib — · Active, not recruiting
- Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer Phase 2 · Active, not recruiting
- Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) Phase 3 · Active, not recruiting
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed